Kringle Pharma, Inc. (4884) AI Stock Analysis

• Market Cap: ¥3.48B
• Dividend Yield: N/A
• Average Volume (3M): 129.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: -8.56%
• EPS Growth: -7.26%
• Country: JP
• Employees: 15
• Sector: Healthcare
• Sector Strength: 52
• Industry: Biotechnology
• EPS (TTM): -33.20
• Shares Outstanding: 6,999,200
• 10 Day Avg. Volume: 88,880
• 30 Day Avg. Volume: 129,693
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: ―

Kringle Pharma's stock score is weighed down by significant financial performance challenges, including consistent net losses and negative cash flows, despite a strong balance sheet free of debt. Technical analysis shows mixed signals with some upward momentum, but a potential overbought condition. The valuation is weak with a negative P/E ratio and no dividend yield, indicating the stock is currently not profitable. These factors combine to give the stock a moderate score, reflecting the potential for risk given the current financial and market conditions.

Kringle Pharma, Inc. Business Overview & Revenue Model

Company Description

Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.

How the Company Makes Money

Kringle Pharma, Inc. generates revenue through the development and commercialization of its proprietary therapeutic products. The company primarily earns money by advancing its drug candidates through clinical trials and subsequently licensing these products to pharmaceutical companies. Revenue streams include milestone payments from partnerships, licensing agreements, and potential royalties from product sales once the therapies reach the market. Strategic collaborations with other biotech and pharma companies also play a significant role in funding its research and development efforts, contributing to its earnings.

Kringle Pharma, Inc. Financial Statement Overview

Summary

Kringle Pharma faces significant profitability challenges with consistent net losses and negative cash flows. While the company's balance sheet is strengthened by a lack of debt and a high equity ratio, the unprofitability and reliance on financing activities present risks. The biotechnology industry demands substantial R&D investments, which may further pressure financial stability unless revenue growth and operational efficiency improve.

Income Statement

Kringle Pharma shows a consistent decline in revenue from 2022 to 2024, with TTM revenue of 79.47 million, down from 80.03 million annually. The gross and net profit margins are negative, indicating unprofitability, with significant EBIT and net income losses. Despite a slight revenue uptick between 2023 and 2024, the overall trend remains negative.

Balance Sheet

The company has no debt, resulting in a favorable debt-to-equity ratio. However, the return on equity is negative due to consistent net losses. The equity ratio remains strong, indicating a solid equity base compared to total assets, though profitability issues persist.

Cash Flow

Negative operating and free cash flows highlight the company's cash burn issue. The lack of positive cash flow from operations paired with negative free cash flow to net income ratio raises concerns about cash sustainability and operational efficiency. Financing cash inflows are notable, but reliance on external funding is a potential risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	72.90M	80.04M	69.25M	391.83M	289.76M	467.62M
Gross Profit	72.90M	80.04M	69.25M	303.42M	218.16M	467.62M
EBITDA	-901.23M	-817.88M	-852.66M	-330.34M	-357.88M	-171.60M
Net Income	-902.27M	-756.45M	-854.15M	-331.83M	-301.17M	-117.83M
Balance Sheet
Total Assets	2.29B	2.76B	2.62B	3.21B	2.64B	2.35B
Cash, Cash Equivalents and Short-Term Investments	1.89B	2.31B	2.14B	2.76B	2.14B	2.10B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	681.40M	648.92M	596.95M	419.50M	129.48M	161.72M
Stockholders Equity	1.61B	2.11B	2.02B	2.79B	2.51B	2.19B
Cash Flow
Free Cash Flow	0.00	-661.17M	-689.10M	15.80M	-560.92M	-146.46M
Operating Cash Flow	0.00	-661.17M	-689.10M	15.80M	-560.92M	-146.46M
Investing Cash Flow	0.00	-121.36M	-120.88M	-254.38M	0.00	0.00
Financing Cash Flow	0.00	838.23M	69.16M	603.11M	595.90M	2.08B

Kringle Pharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 497.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4884, the sentiment is Neutral. The current price of 497 is above the 20-day moving average (MA) of 491.25, below the 50-day MA of 606.24, and below the 200-day MA of 810.57, indicating a neutral trend. The MACD of -26.65 indicates Negative momentum. The RSI at 39.75 is Neutral, neither overbought nor oversold. The STOCH value of 48.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4884.

Kringle Pharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4884	54 Neutral	¥3.48B	―		―	-8.56%	-7.26%
Sector *	51 Neutral	$7.95B	-0.38	-43.43%	2.22%	22.30%	-1.83%
30O	―	€52.09M	―	-96.20%	―	―	―
4594	56 Neutral	¥8.58B	―		―	1254.76%	33.94%
3750	54 Neutral	¥8.35B	55.07		―	-92.12%	-3310.68%
4588	44 Neutral	¥16.59B	―		―	-9.04%	2.12%
4598	28 Underperform	¥6.89B	―		―	―	20.41%

Kringle Pharma, Inc. Corporate Events

Kringle Pharma Releases Updated Analyst Report to Enhance Investor Insight

Kringle Pharma, Inc. has announced the release of an updated analyst report by Shared Research Inc., providing a comprehensive analysis of the company’s business structure and growth strategies. This report is intended to enhance investors’ understanding and facilitate informed investment decisions, reflecting Kringle Pharma’s commitment to transparency and constructive dialogue with shareholders.

Kringle Pharma Reports Flat Sales and Continued Losses

Kringle Pharma, Inc. reported its financial results for the quarter ending December 31, 2024, showing net sales of 18 million yen, which remained flat compared to the previous year. However, the company experienced an operating and ordinary profit loss of 212 million yen, indicating ongoing financial challenges. The financial forecast for the fiscal year ending September 30, 2025, suggests expected net sales of 272 million yen with a projected loss continuing, reflecting the company’s ongoing struggle to improve profitability.